vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and ORMAT TECHNOLOGIES, INC. (ORA). Click either name above to swap in a different company.

ORMAT TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($276.0M vs $191.2M, roughly 1.4× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 19.6%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 11.0%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Ormat Technologies, Inc. is an international company based in Reno, Nevada, United States. Ormat supplies alternative and renewable geothermal energy technology. The company has built over 190 power plants and installed over 3,200 MW of output. As of January 2021 it owns and operates 933 MW of geothermal and recovered energy based power plants. Ormat has supplied over 1000 turbochargers worldwide, in North America, South America, Europe, Australia, and Asia. The company's products also includ...

AXSM vs ORA — Head-to-Head

Bigger by revenue
ORA
ORA
1.4× larger
ORA
$276.0M
$191.2M
AXSM
Growing faster (revenue YoY)
AXSM
AXSM
+37.8% gap
AXSM
57.4%
19.6%
ORA
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
48.1%
11.0%
ORA

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AXSM
AXSM
ORA
ORA
Revenue
$191.2M
$276.0M
Net Profit
$31.4M
Gross Margin
28.6%
Operating Margin
-33.1%
15.4%
Net Margin
11.4%
Revenue YoY
57.4%
19.6%
Net Profit YoY
-23.2%
EPS (diluted)
$0.51

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
ORA
ORA
Q1 26
$191.2M
Q4 25
$196.0M
$276.0M
Q3 25
$171.0M
$249.7M
Q2 25
$150.0M
$234.0M
Q1 25
$121.5M
$229.8M
Q4 24
$118.8M
$230.7M
Q3 24
$104.8M
$211.8M
Q2 24
$87.2M
$213.0M
Net Profit
AXSM
AXSM
ORA
ORA
Q1 26
Q4 25
$-28.6M
$31.4M
Q3 25
$-47.2M
$24.1M
Q2 25
$-48.0M
$28.0M
Q1 25
$-59.4M
$40.4M
Q4 24
$-74.9M
$40.8M
Q3 24
$-64.6M
$22.1M
Q2 24
$-79.3M
$22.2M
Gross Margin
AXSM
AXSM
ORA
ORA
Q1 26
Q4 25
28.6%
Q3 25
25.6%
Q2 25
24.3%
Q1 25
31.7%
Q4 24
31.9%
Q3 24
27.8%
Q2 24
28.8%
Operating Margin
AXSM
AXSM
ORA
ORA
Q1 26
-33.1%
Q4 25
-13.8%
15.4%
Q3 25
-27.0%
16.2%
Q2 25
-24.5%
15.1%
Q1 25
-46.9%
22.2%
Q4 24
-61.1%
21.3%
Q3 24
-59.8%
16.8%
Q2 24
-89.5%
16.5%
Net Margin
AXSM
AXSM
ORA
ORA
Q1 26
Q4 25
-14.6%
11.4%
Q3 25
-27.6%
9.7%
Q2 25
-32.0%
12.0%
Q1 25
-48.9%
17.6%
Q4 24
-63.1%
17.7%
Q3 24
-61.7%
10.4%
Q2 24
-91.0%
10.4%
EPS (diluted)
AXSM
AXSM
ORA
ORA
Q1 26
Q4 25
$-0.55
$0.51
Q3 25
$-0.94
$0.39
Q2 25
$-0.97
$0.46
Q1 25
$-1.22
$0.66
Q4 24
$-1.54
$0.67
Q3 24
$-1.34
$0.36
Q2 24
$-1.67
$0.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
ORA
ORA
Cash + ST InvestmentsLiquidity on hand
$305.1M
$147.4M
Total DebtLower is stronger
$70.0M
$2.7B
Stockholders' EquityBook value
$2.5B
Total Assets
$713.6M
$6.2B
Debt / EquityLower = less leverage
1.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
ORA
ORA
Q1 26
$305.1M
Q4 25
$322.9M
$147.4M
Q3 25
$325.3M
$79.6M
Q2 25
$303.0M
$88.5M
Q1 25
$300.9M
$112.7M
Q4 24
$315.4M
$94.4M
Q3 24
$327.3M
$88.1M
Q2 24
$315.7M
$66.3M
Total Debt
AXSM
AXSM
ORA
ORA
Q1 26
$70.0M
Q4 25
$2.7B
Q3 25
Q2 25
Q1 25
Q4 24
$2.3B
Q3 24
Q2 24
Stockholders' Equity
AXSM
AXSM
ORA
ORA
Q1 26
Q4 25
$88.3M
$2.5B
Q3 25
$73.7M
$2.5B
Q2 25
$73.1M
$2.5B
Q1 25
$53.2M
$2.5B
Q4 24
$57.0M
$2.4B
Q3 24
$92.9M
$2.4B
Q2 24
$102.9M
$2.4B
Total Assets
AXSM
AXSM
ORA
ORA
Q1 26
$713.6M
Q4 25
$689.8M
$6.2B
Q3 25
$669.3M
$6.1B
Q2 25
$639.8M
$6.0B
Q1 25
$596.7M
$5.8B
Q4 24
$568.5M
$5.7B
Q3 24
$561.5M
$5.6B
Q2 24
$548.2M
$5.5B
Debt / Equity
AXSM
AXSM
ORA
ORA
Q1 26
Q4 25
1.05×
Q3 25
Q2 25
Q1 25
Q4 24
0.97×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
ORA
ORA
Operating Cash FlowLast quarter
$105.0M
Free Cash FlowOCF − Capex
$-40.0M
FCF MarginFCF / Revenue
-14.5%
Capex IntensityCapex / Revenue
52.6%
Cash ConversionOCF / Net Profit
3.35×
TTM Free Cash FlowTrailing 4 quarters
$-284.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
ORA
ORA
Q1 26
Q4 25
$-18.7M
$105.0M
Q3 25
$1.0M
$45.2M
Q2 25
$-32.4M
$96.9M
Q1 25
$-43.4M
$88.0M
Q4 24
$-26.2M
$158.6M
Q3 24
$-18.6M
$106.4M
Q2 24
$-30.1M
$30.7M
Free Cash Flow
AXSM
AXSM
ORA
ORA
Q1 26
Q4 25
$-18.7M
$-40.0M
Q3 25
$988.0K
$-102.1M
Q2 25
$-32.4M
$-37.9M
Q1 25
$-43.7M
$-104.6M
Q4 24
$-26.2M
$30.9M
Q3 24
$-18.7M
$-3.3M
Q2 24
$-30.2M
$-116.1M
FCF Margin
AXSM
AXSM
ORA
ORA
Q1 26
Q4 25
-9.6%
-14.5%
Q3 25
0.6%
-40.9%
Q2 25
-21.6%
-16.2%
Q1 25
-36.0%
-45.5%
Q4 24
-22.1%
13.4%
Q3 24
-17.9%
-1.6%
Q2 24
-34.6%
-54.5%
Capex Intensity
AXSM
AXSM
ORA
ORA
Q1 26
Q4 25
0.0%
52.6%
Q3 25
0.0%
59.0%
Q2 25
0.0%
57.6%
Q1 25
0.3%
83.8%
Q4 24
0.0%
55.4%
Q3 24
0.1%
51.8%
Q2 24
0.1%
69.0%
Cash Conversion
AXSM
AXSM
ORA
ORA
Q1 26
Q4 25
3.35×
Q3 25
1.87×
Q2 25
3.45×
Q1 25
2.18×
Q4 24
3.89×
Q3 24
4.82×
Q2 24
1.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXSM
AXSM

Product sales, net$189.4M99%
Royalty revenue and milestone revenue$1.8M1%

ORA
ORA

Electricity$186.6M68%
Products$63.1M23%
Energy Storage Segment$26.3M10%
Product Segment$1.2M0%

Related Comparisons